Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy

Narcolepsy Clinical Trial

Official title:

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00078377
• Other study ID #: C10953/3020/NA/MN
• Status: Completed
• Phase: Phase 3
• First received: February 24, 2004
• Last updated: July 12, 2013
• Start date: March 2004
• Est. completion date: January 2005

Study information

• Verified date: July 2013
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with narcolepsy by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500) and by the Clinical Global Impressions of Change (CGI-C) ratings (as related to general condition) at week 12 (or last postbaseline observation)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 196
• Est. completion date: January 2005
• Est. primary completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Diagnosis and Criteria for Inclusion:

Patients are included in the study if all of the following criteria are met:

• Written informed consent is obtained

• The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive)

• The patient has a complaint of excessive sleepiness

• The patient has a current diagnosis of narcolepsy according to ICSD criteria.

• The patient is in good health as determined by a medical and psychiatric history, physical examination, electrocardiogram (ECG), and serum chemistry, hematology, and urinalysis.

• Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of the study.

• The patient has a mean sleep latency of 6 minutes or less as determined by the Multiple Sleep Latency Test (MSLT) (performed at 0900, 1100, 1300, and 1500).

• The patient has a CGI-S (Clinical Global Impression of Severity of Illness) rating of 4 or more.

• The patient does not have any medical or psychiatric disorders that could account for the excessive daytime sleepiness.

• The patient is able to complete self rating scales and computer-based testing.

• The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

Criteria for Exclusion:

Patients are excluded from participating in this study if 1 or more of the following criteria are met. The patient:

• has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)

• has a probable diagnosis of a current sleep disorder other than narcolepsy

• consumed caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day

• used any prescription drugs disallowed by the protocol or clinically significant use of over the-counter (OTC) drugs within 7 days before the second screening visit

• has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)

• has a positive UDS at the screening visit, without medical explanation

• has a clinically significant deviation from normal in the physical examination

• is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)

• has used an investigational drug within 1 month before the screening visit

• has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)

• has a known clinically significant drug sensitivity to stimulants or modafinil

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Disorders of Excessive Somnolence
• Narcolepsy

Intervention

Drug:
• Armodafinil
Armodafinil 250 mg once daily in the morning
• Armodafinil
Armodafinil 150 mg once daily in the morning
• Placebo
Matching placebo tablets once daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks	The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a subject to remain awake. Long latencies to sleep are indicative of a patient's ability to remain awake. The change from baseline in the mean sleep latency from the MWT (average of 4 tests at 0900, 1100, 1300, and 1500) was analyzed at weeks 4, 8, and 12. The primary efficacy variable was the mean change from the baseline assessment in MWT sleep latency as assessed at week 12 (or last post-baseline visit).	change from baseline at 12 weeks	No
Primary	Change From Baseline in Clinical Global Impression of Change (CGI-C) Score at 12 Weeks	Number of participants who had at least minimal improvement in CGI-C ratings at Week 12 or last post-baseline visit. The CGI-C uses the following categories and scoring assignments: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; and 7=Very much worse. Severity of illness was assessed at baseline by the CGI-S, which consists of the following categories: 1=Normal (shows no signs of illness); 2=Borderline ill; 3=Mildly (Slightly) ill; 4=Moderately ill; 5=Markedly ill; 6=Severely ill; and 7=Among the most extremely ill patients.	change from baseline at 12 weeks	No